X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
HALIX will provide manufacturing and clinical supply of NovalGen's therapies as part of this partnership. HALIX has supported NovalGen with the successful completion of GMP manufacture of NVG-111 from drug substance up to drug product and final release.
Lead Product(s): NVG-111
Therapeutic Area: Oncology Product Name: NVG-111
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: NovalGen
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership February 22, 2021
Details:
Under the agreement, HALIX will provide commercial manufacturing of drug substance at its state-of-the-art cGMP facility at the Leiden Bio Science Park in the Netherlands. To meet the increased demand, HALIX expands with two additional viral vector production lines.
Lead Product(s): ChAdOx1 nCoV-19
Therapeutic Area: Infections and Infectious Diseases Product Name: AZD1222
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 08, 2020
Details:
Under the collaboration, Halix will utilise its brand new state-of-the-art GMP facilities with capacity up to 1,000 L SUB scale, supporting the manufacture of ChAdOx1 nCoV-19 clinical trial material.
Lead Product(s): ChAdOx1 nCoV-19
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: University’s Jenner Institute
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 15, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
